MRK gained around $20 billion in market cap value on this news. (By comparison AMRN has a market cap closer to $2 billion in total.) I wonder if MRK would ever consider looking at Vascepa as an adjunct drug to use with their Keytruda drug for Cancer? MRK has 100's of studies using Keytruda, I wish someone would determine if Vascepa used with it would give better results.
Anyway, if MRK ever wanted to use its stock as currency to do any acquisitions, now would be the time.